Vaccine Effectiveness in Preventing Deaths in People with Severe Acute Respiratory Syndrome Due to COVID-19 in Blumenau, Brazil, 2021

Overview

Journal Epidemiol Serv Saude

Date 2024 Feb 21

PMID 38381873

Authors

Emanuelle Renck

Caroline Beatriz Zipper

Marcio Rodrigues Fabrino Junior

Luisa Andrea Torres Salgado

Adriel Rowe

Ernani Tiaraju de Santa Helena

Affiliations

Soon will be listed here.

Abstract

Objective: to analyze the vaccine effectiveness in preventing deaths attributed to severe acute respiratory syndrome due to COVID-19 (SARS/COVID-19) in adults and the elderly, in Blumenau, state of Santa Catarina, Brazil, 2021.

Conclusion: vaccines proved to be effective in reducing case fatality ratio due to SARS/COVID-19 in individuals ≥ 20 years old.

References

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Higdon M, Wahl B, Jones C, Rosen J, Truelove S, Baidya A . A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. Open Forum Infect Dis. 2022; 9(6):ofac138. PMC: 9047227. DOI: 10.1093/ofid/ofac138. View

Sullivan S, Tchetgen Tchetgen E, Cowling B . Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. Am J Epidemiol. 2016; 184(5):345-53. PMC: 5013887. DOI: 10.1093/aje/kww064. View

Patel M, Bergeri I, Bresee J, Cowling B, Crowcroft N, Fahmy K . Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine. 2021; 39(30):4013-4024. PMC: 8166525. DOI: 10.1016/j.vaccine.2021.05.099. View

Starrfelt J, Danielsen A, Buanes E, Juvet L, Lyngstad T, Ro G . Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021. BMC Med. 2022; 20(1):278. PMC: 9436448. DOI: 10.1186/s12916-022-02480-4. View

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

Orellana J, Cunha G, Marrero L, da Costa Leite I, Domingues C, Horta B . [Changes in the pattern of COVID-19 hospitalizations and deaths after substantial vaccination of the elderly in Manaus, Amazonas State, Brazil]. Cad Saude Publica. 2022; 38(5):PT192321. DOI: 10.1590/0102-311XPT192321. View

Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W . Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2021; 114:252-260. PMC: 8595975. DOI: 10.1016/j.ijid.2021.11.009. View

Ranzani O, Bastos L, Gelli J, Marchesi J, Baiao F, Hamacher S . Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Lancet Respir Med. 2021; 9(4):407-418. PMC: 7834889. DOI: 10.1016/S2213-2600(20)30560-9. View

10.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

11.

Peres I, Bastos L, Gelli J, Marchesi J, Dantas L, Antunes B . Sociodemographic factors associated with COVID-19 in-hospital mortality in Brazil. Public Health. 2021; 192:15-20. PMC: 7836512. DOI: 10.1016/j.puhe.2021.01.005. View

12.

Mascarello K, Vieira A, de Souza A, Marcarini W, Barauna V, Maciel E . COVID-19 hospitalization and death and relationship with social determinants of health and morbidities in Espírito Santo State, Brazil: a cross-sectional study. Epidemiol Serv Saude. 2021; 30(3):e2020919. DOI: 10.1590/S1679-49742021000300004. View

13.

Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z . Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 2020; 12(13):12493-12503. PMC: 7377860. DOI: 10.18632/aging.103579. View

14.

Niquini R, Lana R, Pacheco A, Cruz O, Coelho F, Carvalho L . Description and comparison of demographic characteristics and comorbidities in SARI from COVID-19, SARI from influenza, and the Brazilian general population. Cad Saude Publica. 2020; 36(7):e00149420. DOI: 10.1590/0102-311x00149420. View

15.

de Jesus M, Hojo-Souza N, de Moraes T, Guidoni D, de Souza F . Profile of Brazilian inpatients with COVID-19 vaccine breakthrough infection and risk factors for unfavorable outcome. Rev Panam Salud Publica. 2022; 46:e106. PMC: 9395277. DOI: 10.26633/RPSP.2022.106. View

16.

Sousa E, Gaido S, Sousa R, Cardoso O, de Matos Neto E, Menezes Junior J . Profile of hospital admissions and deaths due to severe acute respiratory syndrome caused by COVID-19 in Piauí, Brazil: a descriptive study, 2020-2021. Epidemiol Serv Saude. 2022; 31(1):e2021836. DOI: 10.1590/S1679-49742022000100009. View

17.

Cerqueira-Silva T, Andrews J, Boaventura V, Ranzani O, Oliveira V, Paixao E . Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect Dis. 2022; 22(6):791-801. PMC: 8971277. DOI: 10.1016/S1473-3099(22)00140-2. View